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OBJECTIVE: Depression is a frequent side effect of interferon therapy in patients with chronic hepatitis C (CHC).
The aim of this study was to identify baseline and on-treatment predictors of depression in CHC
patients receiving peginterferon and ribavirin.
METHODS: In total, 201 prior nonresponders with advanced fibrosis were treated with peginterferon alfa-2a and
ribavirin for 24 wk in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial. Of these,
74 continued on antiviral therapy through week 48. Mood states were assessed with the Beck
Depression Inventory II and the Composite International Diagnostic Interview. Plasma cortisol and
whole blood serotonin levels were measured in 101 subjects at weeks 0, 4, 24, 48, and 72.
RESULTS: The incidence of interferon-induced depression was 23% and 42% at weeks 24 and 48, respectively.
Although 22% of patients had baseline depression, the absence of a week 20 virological response
was the only independent predictor of interferon-induced depression at week 24 (P = 0.0009).
Plasma cortisol levels did not change during treatment nor correlate with depression. In contrast,
whole blood serotonin/platelet levels significantly decreased during treatment, but did not correlate
with interferon-induced depression through week 24 (P = 0.35), nor through week 48 (P = 0.51).
CONCLUSION: Depression during peginterferon and ribavirin therapy was associated with a lower antiviral response.
The significant reduction in whole blood serotonin levels over time suggest that further studies of
the serotonergic pathway are warranted to identify the mediators of interferon-induced depression.
(Am J Gastroenterol 2008;103:2766–2775)
INTRODUCTION
Commonly reported psychiatric side effects of interferon
therapy include depression, anxiety, and irritability, although
mood changes associated with the underlying medical con-
dition can be difficult to discern from the medication effects
(1, 2). Peginterferon and ribavirin combination therapy is as-
sociated with a clinically significant depression in 30–50%
of patients with chronic hepatitis C (CHC) treated in clinical
trials as well as in clinical practice (3, 4). Using a battery of
objective and validated neuropsychological tests, cognitive
function did not worsen during peginterferon and ribavirin
treatment of CHC patients with advanced fibrosis (5). How-
ever, many CHC patients receiving antiviral therapy complain
This is publication number 24 from the HALT-C Trial Group.
not only of impaired cognition but also of moderate-to-severe
depression, anxiety, and fatigue, as measured by self-report
and interviewer-administered questionnaires (5, 6). As psy-
chiatric side effects are a leading cause of interferon dose
reductions or premature discontinuation, further studies re-
garding the incidence and pathogenesis of interferon-induced
mood alterations are warranted.
Selective serotonin reuptake inhibitors (SSRI) can effec-
tively treat and potentially prevent the depression seen in
patients receiving interferon (7–10). However, the studies re-
ported to date have identified different, and sometimes, con-
flicting predictors of interferon-induced depression includ-
ing baseline mood status (10–13). Furthermore, the mech-
anism(s) of interferon-induced depression have not been
elucidated, although a few studies have suggested a possi-
ble role for changes in the hypothalamic–pituitary adrenal
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(HPA) axis as well as the central catecholamine and sero-
tonin systems (14–17). The Hepatitis C Antiviral Long-term
Treatment against Cirrhosis (HALT-C) trial is a prospec-
tive multicenter study designed to investigate the potential
benefit of maintenance peginterferon in reducing the rate of
disease progression in prior interferon nonresponders with
advanced fibrosis (18, 19). During the lead-in phase, all pa-
tients received peginterferon alfa-2a and ribavirin for 24 wk,
and subjects who remained viremic at week 20 were eligible
for randomization to low-dose peginterferon or no treatment.
The subjects who had undetectable HCV RNA by polymerase
chain reaction (PCR) at week 20 continued in the responder
arm of the study to complete 48 wk of antiviral treatment. In
this article, the incidence, baseline predictors, and potential
biomarkers associated with mood disturbances in 201 HALT-
C patients are reported. It was hypothesized that depressive
symptoms at baseline would predict depression during an-
tiviral therapy, and that depression scores would positively
correlate with plasma cortisol levels and negatively correlate
with whole blood serotonin levels.
METHODS
Patient Population and Study Design
The 201 patients enrolled in this ancillary study were re-
cruited from the University of Michigan (UM) and the Uni-
versity of Southern California (USC). The inclusion criteria
for the HALT-C trial were detectable serum HCV RNA, a
liver biopsy within 12 months of enrollment showing an Ishak
fibrosis score of 3–6, and a lack of response to previous in-
terferon treatment. The exclusion criteria included any other
co-existent liver disorder, a history of hepatic decompensa-
tion, and intolerance to interferon (19). Additional exclusion
criteria were an active use of illicit drugs, ongoing excessive
alcohol consumption, a history of suicide attempt or hospi-
talization for depression within the past 5 yr, and a history
of severe or incapacitating psychiatric condition within the
past 6 months. A history of major depression that was not
severe or incapacitating at enrollment was not considered as
an exclusion criterion. All patients provided written informed
consent to participate in the HALT-C trial as well as in this
ancillary study at UM and USC.
All subjects were treated with peginterferon alfa-2a at a
dose of 180 µg per week (Pegasys; Roche Laboratories, Nut-
ley, NJ) and ribavirin in doses of 1.0–1.2 grams per day (Cope-
gus; Roche Laboratories). Serum HCV RNA testing was done
using the quantitative COBAS Amplicor HCV Monitor test
(Roche Molecular Diagnostics, Branchburg, NJ) with a lower
detection limit of 600 IU/mL and the qualitative COBAS Am-
plicor HCV test (Roche Molecular Diagnostics) with a lower
detection limit of 100 IU/mL. Patients who tested HCV RNA
negative at week 20 were considered virological responders
and continued with combination antiviral therapy for 48 wk
in the responder arm of the study. Patients without detectable
HCV RNA at week 72 were considered to have a sustained
virological response (SVR). Adherence was defined as tak-
ing at least 80% of the prescribed peginterferon and ribavirin
dose through week 12 and week 20 (20).
Psychiatric Assessment
The Composite International Diagnostic Interview (CIDI) is a
standardized instrument for the assessment of mental health
disorders according to the Diagnostic and Statistical Man-
ual of Mental Disorders-IV (DSM-IV) criteria (21). In this
study, the computerized lifetime (LT) version of the CIDI that
included depression, anxiety, alcohol, and substance abuse
modules was self-administered at baseline (week 0). Dur-
ing antiviral therapy, the 12-month version of the depression
module alone was administered at weeks 24, 48, and 72.
The Beck Depression Inventory (BDI)-II, is a 21-item, self-
administered questionnaire designed to screen for depressive
symptoms over the previous 2 wk (22). The BDI was ad-
ministered at weeks 0 (baseline), 4, 12, 24, 36, 48, 60, and
72. A score <10 was considered as no depression, 11–14
as minimal, 15–19 as mild, 20–28 as moderate, and >28 as
severe depression. A lifetime alcohol consumption was esti-
mated using a modification of the Skinner survey (23). Years
of education were coded by the highest level completed, and
occupation was categorized on a scale of 1–6 with 1 = un-
skilled/farm labor and 6 = professional/technical (24).
Definition of Depression
Depression at baseline (week 0) was defined as either a BDI
≥11 or fulfilling the DSM-IV criteria for major depression
during the previous 12 months on the CIDI. For subjects
without baseline depression, interferon-induced depression
was defined at each postbaseline time point as a BDI ≥11 or
fulfilling DSM-IV criteria for depression via the CIDI. For
subjects with baseline depression (i.e., baseline BDI-II ≥11
or CIDI criteria for depression), interferon-induced depres-
sion was defined at each postbaseline time point as a BDI
score that had increased by 6 points or more compared with
baseline. The rationale for this criterion includes prior stud-
ies that used a numerical increase in BDI-II scores or other
self-rating scales to define interferon-induced depression in
subjects with baseline depression (25, 26). The use of antide-
pressants such as SSRI’s (e.g., fluoxetine) and non-SSRI’s
(e.g., nortriptyline) was recorded, but was not part of the def-
inition of depression.
Cortisol and Serotonin Assays
In subjects enrolled at UM, fasting morning blood samples
were processed immediately and stored at –70◦C. The sam-
ples were tested in batches to minimize interassay variability.
Plasma cortisol was measured at the UM Hospital Chemistry
Laboratory by a chemiluminescent immunoassay on an Advia
Centaur analyzer (Bayer Diagnostics, Tarrytown, NY). The
coefficient of variation for the cortisol assay varied from 4.3%
to 8.0% over the reference range for morning cortisol levels of
7–22 µg/dL (25). Whole blood serotonin was measured using
a high-pressure liquid chromatography method with fluores-
cence detection (Bioanalytical Systems, West Lafayette, IN)
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(26). The dynamic range of the assay was 1–10,000 nM/L,
with a coefficient of variation of 3.0%. Samples with low or
undetectable whole blood serotonin levels were repeated to
verify the results. As platelets are a rich source of serotonin
in whole blood, and interferon therapy is known to reduce
platelet counts, the whole blood serotonin/platelet ratio was
analyzed as a biomarker of whole body serotonin stores.
Data Analyses
A Kaplan-Meier product-moment analysis was used to es-
timate the cumulative incidence of depression at week 24
and week 48. A Cox-proportional hazard analysis was used
to identify baseline predictors associated with depression in
both week 24 and week 48 cohorts. In addition, adherence
to antiviral medications as well as week 12 virological re-
sponse (i.e., decline in HCV RNA by >2 log10 or unde-
tectable) and week 20 virological response (i.e., HCV RNA
undetectable) were tested as predictors of depression. The as-
sociation of each variable with interferon-induced depression
was tested alone, and a multivariable model was computed
that included all variables with P < 0.15 and controlling for
baseline depression. The association between the biological
markers and baseline BDI-II scores in the UM patients was
evaluated by the Pearson correlation coefficient. The change
over time in the biological markers was evaluated using a
repeated-measures analysis of variance (ANOVA). The asso-
ciation between the changes in biomarkers and development
of interferon-induced depression through weeks 24 and 48
was evaluated using the Cox proportional hazard analysis.
All analyses were carried out using the SAS statistical soft-
ware version 9.1 (SAS Institute, Inc., Cary, NC).
RESULTS
Study Population
The baseline characteristics of the 102 subjects enrolled at
UM and the 99 subjects enrolled at USC were comparable
in all respects except for the proportion of Hispanics, num-
ber of HCV genotype 1 patients, and the duration of HCV
infection. Therefore, the data from the 201 subjects were
grouped together for analysis (Table 1). At week 24, 185 sub-
jects completed the BDI-II, while the remaining 16 subjects
had withdrawn from the HALT-C study (N = 13), the cog-
nitive study (N = 2), or failed to complete the BDI-II (N =
1). Seventy-four of the 201 patients (37%) had undetectable
HCV RNA at week 20 and continued in the responder arm of
the trial through week 48. The remaining 127 subjects with
detectable HCV RNA at week 20 had antiviral therapy dis-
continued at week 24 and were eligible for the randomized
phase of HALT-C.
The baseline features of the 201 HALT-C patients demon-
strated a mean age of 50 yr and 71% were male (Table 1).
The mean baseline BDI-II score was 6.9, with 22% having
a score greater than 11, 5.5% having a score ≥20, and 7%
meeting the DSM-IV criteria for depression in the previous
12 months. The 51 HALT-C patients (25%) with baseline
depression were significantly more likely to be female, non-
Caucasian, and have lower educational levels compared with
the 150 nondepressed patients (P < 0.05). In addition, the
depressed subjects were significantly more likely to be re-
ceiving an antidepressant or anxiolytic at week 0. Finally, the
whole blood serotonin/platelet levels tended to be lower in
the patients with baseline depression (P = 0.10).
Depression Through Week 24
The cumulative incidence of interferon-induced depression
in the 201 subjects increased from 2% at week 4 to 6% at
week 12 and 22% at week 24 (Fig. 1). The use of antidepres-
sant/anxiolytic medications at baseline (P = 0.054) and the
failure to achieve a week 12 virological response (P = 0.018)
or week 20 virological response (P = 0.0023) were associated
with interferon-induced depression (Table 2). As the HALT-C
study had called for 24 wk of antiviral therapy, and there was
a significant interaction between week 12 and week 20 viro-
logical response (kappa = 0.60, P < 0.0001), only week 20
virological response and other variables with P < 0.15 were
used in the multivariate model. In the multivariable analysis,
only the absence of a week 20 virological response remained
significantly associated with interferon-induced depression
(P = 0.0009).
Among the 150 subjects without baseline depression, the
cumulative incidence of depression was 2% at week 4, 7%
at week 12, and 21% at week 24 (Fig. 1). Similarly, in the
51 subjects who met the criteria for baseline depression, the
cumulative incidence of interferon-induced depression was
4% at weeks 4 and 12, and 32% at week 24 (Fig. 1). There-
fore, the incidence of interferon-induced depression was not
significantly different in patients with and without baseline
depression (hazard ratio 1.47, 95% confidence interval [CI]
0.79–2.73, P = 0.22).
Depression Through Week 48
Among the 74 subjects who continued on the antiviral ther-
apy through week 48, 64 (86%) had undetectable HCV RNA
at week 48, and overall 38 (51%) achieved an SVR at week
72. The actuarial incidence of interferon-induced depression
in these subjects increased from 4% at week 4 to 9% at week
24, and 42% at week 48 (Fig. 2). However, none of the base-
line features including baseline BDI-II scores or adherence
to peginterferon or ribavirin were associated with the devel-
opment of depression through week 48 (data not shown).
Among the 66 subjects with available BDI-II scores through
week 72, the mean BDI-II scores at week 72 were signifi-
cantly lower compared with week 24 (4.7 ± 0.7 vs 7.8 ±
0.7, P = 0.0009) and week 48 (4.7 ± 0.7 vs 7.4 ± 0.7, P =
0.0006), demonstrating that interferon-induced depression is
reversible.
Changes in Serum Biomarkers
At baseline, plasma cortisol levels ranged from 2.2 to 24.3
µg/dL, with only 2% of the patients having cortisol levels that
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Table 1. Clinical Characteristics of Overall Study Population and Patients With and Without Baseline Depression
Total Population Baseline Depression No Depression
(N = 201) (N = 51) (N = 150) P Value
Age (yr) 50.23 (7.8) 50.49 (7.2) 50.15 (8.0) 0.79
% female 29 41 25 0.0318
Ethnicity 0.16
% white 71 59 75
% black 1 22 12
% Hispanic 10 14 9
% other 4 6 3
Educational level (yr) 13.38 (2.3) 12.78 (1.6) 13.58 ( 2.5) 0.0096
Occupational codes∗ 4.02 (1.6) 3.71 (1.6) 4.12 (1.6) 0.10
% married 69 57 73 0.0356
Parenteral risk factors
Ever received a transfusion, % 40 53 35 0.0265
Ever experienced needle stick, % 15 20 14 0.34
Ever used needles for recreational drugs, % 45 41 47 0.50
None of the above, % 14 8 17 0.12
Time since last IFN therapy (days) 814.16 (740.42) 857.92 (842.7) 799.29 (704.8) 0.63
% Ishak 5/6 38 39 37 0.81
Log HCV RNA (IU/mL) 6.51 (0.5) 6.58 (0.5) 6.48 (0.5) 0.22
% HCV genotype 1 88 90 87 0.59
Serum ALT (IU/mL) 2.52 (1.95) 2.28 (1.63) 2.60 (2.1) 0.31
Platelets (103/mL) 167.43 (61.0) 166.06 (59.79) 167.90 (61.6) 0.85
% diabetics 25 31 23 0.25
% prior IFN + ribavirin 71 73 71 0.80
Lifetime alcohol consumption (drinks/day) 2.06 2.58 1.89 0.23
BDI-II score 6.86 (6.5) 15.39 (6.3) 3.95 (3.1) <0.0001
% BDI ≥11 22 86 0 <0.0001
CIDI depression (last 12 months) 7% 29% 0% <0.0001
CIDI depression (lifetime) 15% 43% 6% <0.0001
% on anxiolytic/antidepressants 29 55 20 <0.0001
Plasma cortisol (µg/dL) 12.41 (4.5) 12.53 (4.8) 12.36 (4.5) 0.87
Whole blood serotonin (nM/L) 512.73 (371.1) 463.96 (462.9) 530.53 (333.3) 0.50
Whole blood serotonin/platelets (nM/L/ 103 platelets) 3.12 (1.9) 2.60 (2.3) 3.31 (1.8) 0.10
% week 12 virological response 58 59 57 0.85
% week 20 virological response 37 35 37 0.79
% sustained virological response 19 16 20 0.50
% took >80% peginteferon through week 12 76 75 76 0.83
% took >80 % ribavirin through week 12 70 63 72 0.21
% took >80% peginterferon through week 20 67 61 69 0.26
% took >80% ribavirin through week 20 59 49 63 0.09
1 = unskilled labor (N = 3); 2 = semiskilled, operative, service (N = 53); 3 = not in work force >10 yr (N = 21); 4 = skilled labor/craftsman/foreman (N = 25); 5 =
manager/clerical/sales work (N = 53); 6 = professional/technical (N = 43).
Data reported as mean (SD) or %.
IFN = interferon.
exceeded the normal range. There was no significant corre-
lation between the baseline cortisol levels and BDI-II scores.
As noted in Figure 3, plasma cortisol levels decreased slightly
by week 4 and then remained stable at week 24, with no sig-
nificant change over time (P = 0.60). Furthermore, there was
no significant association between cortisol levels and the de-
velopment of interferon-induced depression through week 24
(P = 0.61) or with BDI-II scores through week 24 (data not
shown).
Prior to antiviral therapy, whole blood serotonin levels
ranged from 4 to 2,023 nM/L, while whole blood serotonin
levels normalized to platelet count ranged from 0.02 to 8.80
nM/L/103 platelets. There were no significant correlations
between baseline whole blood or normalized serotonin lev-
els and BDI-II scores (P = 0.59 and P = 0.23, respectively).
The normalized serotonin levels significantly decreased from
baseline through week 24 (P <0.0001) (Fig. 4). However, nei-
ther the changes in normalized serotonin levels nor the whole
blood serotonin levels correlated with interferon-induced de-
pression through week 24 or week 48 (P = 0.35 and P =
0.51, respectively). In addition, there was no significant cor-
relation of these biomarker levels with the BDI-II scores (data
not shown).
DISCUSSION
Previously published studies of mood states in CHC patients
receiving an antiviral therapy have been limited by the small
numbers of patients enrolled, the nonstandardized definitions
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Figure 1. Interferon-induced depression through week 24 in 201
HALT-C patients. The incidence of interferon-induced depression
increased to 23% by week 24. However, the incidence of interferon-
induced depression was not significantly different in the 51 subjects
with baseline depression compared with the 150 subjects without
baseline depression (hazard ratio 1.47, 95% CI 0.79–2.73, P = 0.22).
of depression, and the heterogeneity of antiviral treatment
regimens used (2, 27, 28). In this study, 201 CHC patients with
advanced fibrosis entering a clinical trial of peginterferon and
ribavirin were prospectively assessed for the changes in mood
status over time using a series of validated instruments. The
BDI-II was selected due to its brevity and established utility
Table 2. Bivariate and Multivariable Predictors of Interferon-Induced Depression Through Week 24 (N = 201 HALT-C Patients)
Bivariate Multivariable
Variable Hazard Ratio 95% CI P Value Hazard Ratio 95% CI P Value
Age 0.97 0.94–1.01 0.11 0.97 0.94–1.01 0.22





Education level 1.02 0.91–1.15 0.71
Occupation 1.09 0.90–1.32 0.36
Married 1.00 0.54–1.86 0.99
Baseline BDI-II score 1.01 0.96–1.05 0.76
Parental risk factors
Received transfusion 0.91 0.50–1.66 0.75
Needle stick 1.39 0.67–2.88 0.38
Recreational drugs 1.45 0.80–2.60 0.22
None of above 0.72 0.29–1.83 0.49
Time since last IFN 1.00 1.00–1.00 0.68
Cirrhosis 0.86 0.46–1.60 0.64
Genotype 1 1.51 0.54–4.20 0.44
Antidepressant/anxiolytic at baseline 1.79 0.99–3.23 0.054 1.45 0.73–2.88 0.29
Depression at baseline 1.47 0.79–2.73 0.22 1.01 0.48–2.14 0.98
Diabetes 0.55 0.27–1.33 0.15 0.51 0.21–1.22 0.13
Prior combination therapy 1.48 0.73–2.99 0.27
Total drinks per lifetime 1.00 1.00–1.02 0.10 1.00 1.00–1.02 0.17
Week 20 virologic response 0.29 0.13–0.64 0.0023 0.21 0.08–0.52 0.0009
Week 12 virologic response∗ 0.79 0.27–0.88 0.018
Took >80% peginterferon through week 20 0.76 0.42–1.40 0.37
Took >80% ribavirin through week 20 1.24 0.67–2.31 0.49
Took >80% peginterferon through week 12 0.77 0.40–1.50 0.44
Took >80% ribavirin through week 12 1.12 0.58–2.16 0.75
∗Week 12 virological response defined as a decrease in HCV RNA by > 2log10 IU/mL compared with baseline or undetectable
in detecting depression in patients with medical conditions
(22, 29, 30). Furthermore, the BDI-II has been used in previ-
ous studies of CHC patients and correlated well with mental
health professional assessment of mood disorders (31). The
computerized CIDI depression module that is based upon the
DSM-IV criteria was also used and previously shown to cor-
relate with interviewer-administered questionnaires (21). As
the CIDI is self-administered, this instrument may also be
more likely to detect depression. Overall, 51 (25%) of the
HALT-C patients met the criteria for depression before the
antiviral therapy, although the depression was graded as mild
in most. The high rate of baseline mood disorders may relate
to the referral bias, the requirement for previous nonresponse
to interferon and advanced fibrosis to enter the HALT-C study,
and the prospective characterization of current and lifetime
psychopathology. However, other prospective studies have
also identified a 20–30% prevalence of mood disorders in
CHC patients prior to antiviral therapy (13, 32)
The cumulative incidence of interferon-induced depres-
sion increased to 23% by week 24, a rate that is similar to what
has been reported in other studies (Fig. 1) (4, 27, 32). In addi-
tion, 16 subjects (8%) had to prematurely discontinue therapy
by week 24 due to various adverse events. Furthermore, 33%
of the treated patients took less than 80% of the prescribed
peginterferon dose through week 20 due to a variety of side
effects including neuropsychiatric toxicity. Based upon the
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Figure 2. Interferon-induced depression through week 48 in 74
HALT-C patients. The incidence of interferon-induced depression
continued to increase from 9% at week 24 to 42% at week 48.
studies of interferon therapy in melanoma and CHC patients,
subjects with baseline depression were expected to be at an
increased risk of interferon-induced depression (10, 13, 33).
In support of this, the use of antidepressants/anxiolytics at
baseline was associated with interferon-induced depression
on the univariate analysis (Table 2). Although expected trends
were noted for several other baseline variables (i.e., baseline
depression [P = 0.22], age [P = 0.11]), none remained signif-
icant in the multivariate analysis. The absence of a significant
association of baseline depression with interferon-induced
depression may have been due to the better tolerability of
peginterferon compared with high-dose standard interferon
used in prior studies and the selection of interferon-“tolerant”
patients for the HALT-C study (34, 35). It is also possible that
Study Week
























Figure 3. Morning plasma cortisol levels through week 24 in 101
HALT-C patients. There was no significant change in the mean
plasma cortisol levels over time (P = 0.60). Values plotted as mean
± standard error.







Figure 4. Normalized whole blood serotonin levels through week
24 in 101 HALT-C patients. The y-axis value was determined by
dividing the whole blood serotonin level by the platelet count at
each time point and is reported as the mean ± standard error. The
mean whole blood serotonin/platelet level did significantly decline
during antiviral therapy (P < 0.0001)
the definition of interferon-induced depression used in the
current study differs from that used in prior studies. As men-
tioned, a validated depressive symptom rating scale (i.e., the
BDI-II) and the CIDI were used to define interferon-induced
depression. To address potential ceiling effects with the BDI-
II, an increase in the BDI-II score of >6 points was required
during treatment for subjects with an elevated baseline score
which would change the classification of depression from
minimal to mild and mild to moderate. In addition, prior
studies have suggested that an increase in the BDI-II score
of 6 points is clinically significant (25, 26). An alternative
approach would have been to use a threshold severity con-
struct to define interferon-induced depression (e.g., a BDI-II
score >18). Finally, a frequent assessment of patients during
antiviral therapy by a mental health professional would be
considered the “gold standard” for verifying the presence of
a mood disorder. However, this approach was not feasible due
to logistical considerations.
A significant association between failure to clear HCV
RNA by week 20 and developing depression during the an-
tiviral therapy was observed in the current study. A previous
study suggested that CHC patients with more severe psychi-
atric side effects during treatment were more likely to achieve
a virological response (36). However, this association was not
found in four other studies that demonstrated a negative re-
lationship between fatigue and response to antiviral therapy
(37–40). In the current study, there was no significant differ-
ence in the BDI-II score at week 4 or week 12 compared with
baseline in the week 20 virologic responders versus nonre-
sponders (data not shown). Therefore, the association noted
in our study may have been due, in part, to the sharing of
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HCV RNA test results with patients during the study and the
expected negative impact that the knowledge of persistent
viremia could have on a patient’s mood. Future studies that
blind patients to virological test results may better discern the
biological effect of interferon on mood versus the knowledge
of the treatment response.
The incidence of interferon-induced depression in the sub-
jects who continued beyond 24 wk increased from 9% at week
24 to 42% by week 48 (Fig. 2). These data suggest that the
neuropsychiatric side effects of peginterferon and ribavirin
increase over time. Importantly, however, the mean BDI-II
scores of subjects returned to pretreatment baseline levels
by week 72, demonstrating the reversibility of interferon-
induced depression. The lack of a significant association be-
tween any of the baseline variables and interferon-induced
depression in this subgroup of 74 subjects may, in part, relate
to the smaller sample size and the exclusion of nonresponders
beyond week 24.
In addition to determining the frequency and severity of
interferon-induced depression, the potential mechanism(s)
of neuropsychiatric side effects was explored in the current
study. Previous studies of short-term interferon therapy have
demonstrated dramatic changes in the HPA axis in healthy
individuals and CHC patients (14, 41, 42). Presumably, the
induction of fever and systemic side effects by interferon
can lead to a marked stress response, with characteristic in-
creases in adrenocorticotropin-releasing hormone (ACTH)
and plasma cortisol levels, as previously noted in subjects
with endogenous depression (1). However, studies of pro-
longed interferon therapy demonstrate the development of a
tolerance to this effect (14). As seen in Figure 3, no signifi-
cant changes in plasma cortisol levels were noted over time.
In addition, baseline plasma cortisol levels did not signifi-
cantly correlate with baseline BDI-II scores, and the changes
in cortisol levels over time did not track with the appearance of
interferon-induced depression or serial BDI-II scores. These
data suggest that alterations in the HPA axis as reflected in
morning cortisol levels are not associated with interferon-
induced depression in CHC patients. However, it remains
plausible that more sensitive and specific measurements of
subtle changes in the HPA axis such as the ACTH stimula-
tion test or dexamethasone suppression test could have led to
different results.
Previous studies have demonstrated that interferon can
lead to downregulation of serotonin synthesis in the brain
and depletion of serotonin precursors throughout the body
(16, 43). In addition, depletion of whole body serotonin
stores via interferon-mediated induction of indoleamine-2,3-
dioxygenase activity has been postulated as a potential mech-
anism of interferon-induced depression (44). In the current
study, whole blood serotonin levels were measured, which
include contributions from platelet-derived serotonin. As in-
terferon is known to cause thrombocytopenia via direct ef-
fects on the bone marrow, the changes in normalized whole
blood serotonin to platelet levels were also investigated. At
baseline, a wide range of whole blood serotonin levels were
noted, and subjects with baseline depression tended to have
lower levels (Table 1). However, neither baseline whole blood
nor normalized serotonin levels were associated with base-
line BDI-II scores. Nonetheless, significant changes in nor-
malized whole blood serotonin levels were seen during the
antiviral therapy, although the degree of change did not cor-
relate with the occurrence of depression (Fig. 4) nor with the
serial changes in the BDI-II scores. The lack of an associ-
ation between the changes in whole blood serotonin levels
and interferon-induced depression may have been due to the
discordance between whole blood and intracerebral serotonin
levels. In addition, the nonspecific reduction of platelet count
in treated patients from interferon effects on the bone marrow
may have obscured a relationship. Finally, the use of SSRI’s in
17% of the HALT-C patients during the lead-in phase and 15%
during the responder arm may have confounded a relation-
ship between these parameters. Therefore, investigation of
more sensitive markers of serotonin metabolism such as sero-
tonin gene polymorphisms, serotonin receptor expression in
peripheral lymphocytes, and serum peptidases induced by
interferon would be worthwhile (43–51).
The strengths of the current study include the enrollment
of a large number of well-characterized CHC patients at two
clinical sites with varying ethnicity, age, and gender. In ad-
dition, standardized and objective measures of mood states
were used rather than the subjective clinical assessment of
a hepatologist. Although a formal assessment of suspected
mood disorders by a mental health professional would have
been preferred, this was not feasible. Other strengths of the
current study include the assessment of mood status within
a clinical trial wherein all patients were seen at regular and
frequent intervals and standardized rules for antiviral dose re-
ductions were utilized. Nevertheless, the results of this study
may not be generalizable to other patients with CHC due
to the strict inclusion criteria of the HALT-C trial. In par-
ticular, the inclusion of patients who had previously toler-
ated a course of interferon therapy may have excluded pa-
tients at risk for severe neuropsychiatric toxicity. In addition,
subjects with severe or recent psychopathology at baseline
were excluded from enrollment into this study of long-term
peginterferon therapy. Finally, as in any study that uses a
self-administered questionnaire, some subjects could have
overestimated psychiatric symptoms, while others may have
underestimated their symptoms due to questionnaire fatigue.
However, the cumulative incidence of interferon-induced de-
pression at weeks 24 and 48 is similar to what has been re-
ported in other studies of mood disorders in CHC patients
(36–40).
In summary, the cumulative incidence of interferon-
induced depression in patients receiving peginterferon and
ribavirin enrolled in the HALT-C trial was 23% at week 24
and 42% at week 48. Contrary to initial hypotheses, many pre-
treatment characteristics were not associated with interferon-
induced depression including the baseline depression, liver
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disease severity, and lifetime psychiatric and alcohol con-
sumption history. However, as expected, receiving an antide-
pressant or anxiolytic medication at baseline was associated
with depression, as was the absence of a virological response
at week 12 and week 20. Morning plasma cortisol levels did
not change significantly during therapy and were not asso-
ciated with depression before or during antiviral therapy. In
contrast, normalized serotonin levels decreased significantly
during antiviral therapy, but were not associated with the de-
velopment of interferon-induced depression. Additional stud-
ies of serotonergic pathways in the pathogenesis of mood
disorders during antiviral therapy of CHC are warranted to
improve our understanding of the biological basis of this com-
mon and dose-limiting side effect of the treatment.
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STUDY HIGHLIGHTS
What Is Current Knowledge
 Depression is a common and dose-limiting side effect
of antiviral treatment in hepatitis C patients.
 The incidence, risk factors, and biological basis for
interferon-induced depression are not well established.
 Prior studies have been limited by the small num-
ber of patients enrolled, nonstandardized assessment
of depression, and heterogeneous antiviral treatment
regimens.
What Is New Here
 The incidence of depression was 23% at week 24 and
42% at week 48 in 201 patients who received pegy-
lated interferon and ribavirin combination therapy in
the Hepatitis C Antiviral Long-term Treatment against
Cirrhosis (HALT-C) trial using validated instruments.
 Although 22% of patients had mild depression at base-
line, the absence of virological clearance at week
20 was the only independent predictor of interferon-
induced depression.
 The plasma cortisol levels did not change during treat-
ment nor correlate with depression.
 Significant declines in whole blood serotonin levels
were noted during treatment but did not correlate with
depression. Additional studies of the seratonergic axis
are indicated to further elucidate the mechanism of this
common and dose-limiting side effect of the antiviral
treatment in hepatitis C patients.
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